Health X Platform Ltd · NSE:HEALTHX
Health X Platform — Sastasundar Ventures — Q3 FY2023 Earnings Presentation
26 slides from Health X Platform's earnings presentation, Feb 14, 2023
Slide 1: Regulation 30 intimation letter to stock exchanges
SASTASUNDAR VENTURES LIMITED Azimganj House, 2nd floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335 Email: info@sastasundar.com; Website: www.sastasundarventures.com CIN: L65993WB1989PLC047002 Date: 14‐02‐2023 To To Th
Slide 2: Investor Presentation February 2023
G3SastaSundar Group ————— health & happiness . . u “ is te Investor Presentation February 2023
Slide 3: Safe Harbour
SastaSundar Safe Harbour BI This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar Ventures Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or su
Slide 4: Quote from Prime Minister Narendra Modi on digital age
In this digital age, we have an opportunity to transform the lives of people in ways that were hard _ to imagine in the past. I see technology as a means of empowerment and as a tool that bridges the distance between hope and opportunity in this digital age. Shri Narendra Modi Howble Prime Minister
Slide 5: Management Commentary
Management Commentary GJ sastasundar Dear Shareholders, We are happy to report the performance for the quarter ended 31.12.2022 During the quarter, the revenue has grown by 98% YOY and in comparison to last quarter (Q0Q) by 10%. Our expansion plan is going on as per plans with 7 fulfilment centres (
Slide 6: Management Commentary
Management Commentary GY sastasundar 2. Profitability : We are glad to inform that we are moving towards Cash positive business model (EBITDA+). Our operations in West Bengal are already generating positive cash and we hope to soon report the EBITDA + result at consolidated level (excluding loss ari
Slide 7: Significant Play in Indian ePharma & Pharma eDistribution — High Growth Sectors
KS sastaSundar Significant Play in Indian ePharma & Pharma eDistribution — High Growth Sectors Flipkart ; Health+ * Strategic Partnership with Flipkart ePharma © Market size US$345 mn in 202] 1 * To grow at CAGR of 22% * eB2B platform distributing pharma and other healthcare Retailer Shakti Indian P
Slide 8: Digital Platform of Healthcare
SastaSundar Digital Platform of Healthcare | i Retailer Shakti SGENY arse, B2B Platform B2C Platform Pharmaceutials Diagnostic Pharmacy and & Other Services Wellness Healthcare Products
Slide 9: Health+ Growing Platform in ePharma
ES sastaSundar rp Health + Growing Platform in ePharma Strategic partnership built on strong capabilities 75.10% £3SastaSundar 24.90% GROUP Flipkart + stake health & happiness stake * Large consumer base * Most efficient supply chain & fulfilment capabilities * Established consumer tech capabilities
Slide 10: Pharma eDistribution — Digital Supply Chain of Pharmaceuticals & Other Healthcare Products
KJ sastaSundar Pharma eDistribution — Digital Supply Chain of Pharmaceuticals & Other Healthcare Products * Digital Supply Chain poised to transform the Indian Pharma distribution benefiting everyone with Pharma Companies major beneficiary * Improved Business Forecasting Digital supply chain can low
Slide 11: Structural Shift — Consolidation on way in Indian Pharma Distribution
EY sastaSundar Structural Shift — Consolidation on way in Indian Pharma Distribution Pharmaceutical wholesaling/distribution is highly consolidated industry in most of the developed countries (period last 2 to 3 decades). India to witness similar consolidation in Pharmaceutical In USA, 92% of the ma
Slide 12: Benefitting Pharma & FMCG Cos.
Benefitting Pharma & FMCG Cos. GY sastasundar * End to End tracking of Inventory up to Retailers with real time data * Better managed inventory leading to reduced return of expired stocks ¢ Better production and distribution planning * New drugs can be introduced faster * Huge scope for Pharma Compa
Slide 13: Benefitting Retailers - Transforming Economics & Lives of Retailers
ES sastaSundar Benefitting Retailers - Transforming Economics & Lives of Retailers Retailer Shakti Traditional Distributors Benefits to Retailers . Full visibility of Inventory online Reduction of Inventory Lead Time Sourcing from Multiple Distributors ° 100% fulfilment Lower Working Capital require
Slide 14: Empowering Retailers — One Stop eProcurement Solution
ES) sastaSundar Empowering Retailers — One Stop eProcurement Solution Widest Availability and 100% Genuine High Margins with Fulfilment of Products Products Transparent Pricing Buy Again (65000+ Products) Frequently Bought Recently Repeat Order Purchased New Arrivals By ‘ A Whisper Ultra Bindazzz Go
Slide 15: Genu Path Labs Snapshot
6 GENY [cee., ‘"PATH LABS Snapshot Genu Path Labs, an NABL ACCREDITED LAB, where everything revolves around Meticulous Assay of Quality Evidence. Highly experienced Clinical 3 5 i Team, Advanced High End Lab Equipment, Stringent Quality Norms — EQAS, ILC, Strong Process Control (QuaGen!8) — we emplo
Slide 16: GENU Health app - Under making of Powerful Health Solutions
GENU Health app - Under making of Powerful Health Solutions GY sastasundar * Direct service to the consumers from Genu Path Labs as D2C Brand offering diagnostic oy are = Nd services with seamless integration of technology ‘s = GENU ACCURACY PATHLABS | GUARANTEED * Centred around preventive care, di
Slide 17: Sastasundar Group — Value Proposition
Sastasundar Group — Value Proposition GY sastaSundar Best in class Customer Experience driven by Value Pricing, Quality and Tech * Clear visibility of high growth with EBITDA + model * Capital efficient with high ROCE * Strong MOAT Established Business Technology with highly efficient supply chain M
Slide 18: Leadership Team
. SastaSundar Leadership Team BY = FCA, FCS, FCM by education and is a = FCA by education and is a seasoned seasoned entrepreneur with more than 25 entrepreneur with more than 20 years of years of experience and a social worker. experience in scaling businesses from scratch. = Areas of work include
Slide 19: Q3FY23 Key Financial Highlights
Q3FY23 Key Financial Highlights ES) sastaSundar Revenue from Operations Gross Profit EBITDA 279.8 iC oeee 8.2 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Gross Profit ¥ . Gross Profit for Q3FY23 stood at Rs21.5 crs. Revenue EBITDA Y Gross Profit margins have increased during ¥ Revenue for Q3FY23 stood
Slide 20: Q3 FY23 Consolidated Profit & Loss Statement
Q3 FY23 Consolidated Profit & Loss Statement KY sastaSundar elu Coll Cle OCOD Q3 FY23 Q3 FY22 Q2 FY23 9M FY23 9M FY22 Revenue from Operations 279.8 141.1 98.3% 253.9 10.2% 725.4 465.4 55.9% Cost of Materials Consumed 258.3 132.9 235.0 672.6 434.5 Gross Profit 21.5 8.2 162.2% 18.9 13.8% 52.8 30.9 70.
Slide 21: Annual Financial Highlights
Annual Financial Highlights ESV sastaSundar Rs. In Crs Revenue from Operations Gross Profit _ Mi as ® 4.5% 8.8% 6.5% Mi a3 62% Q2 Ql 540 41 a _ ey 385 a 10 a 134 ~ on a 155 10 ~ ee 200 169 13 134 4 FY22 FY20 FY21 FY22 me ~ Gross Profit Revenue ¥ FY21 gross profit grew by 137% to Rs. 41 crs as compar
Slide 22: Historical Consolidated Profit & Loss Statement
ES sastaSundar Historical Consolidated Profit & Loss Statement Particulars (Rs. Crs) WE Vera Mar-21 Mar-20 Mar-19 Mar-18 Revenue from Operations 623.0 540.0 384.0 215.6 148.3 Cost of Materials Consumed 582.5 492.5 366.9 199.5 140.4 Gross Profit 40.5 47.5 17.1 16.1 7.9 GP % 6.5% 8.8% 4.5% 7.5% 5.3% E
Slide 23: Historical Consolidated Balance Sheet
ES sastaSundar Historical Consolidated Balance Sheet Equity& Liabilities (Rs.Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 § Assets (Rs. Crs) Mar-22 Mar-21 Mar-20 Mar-19 Mar-18 Equity Share Capital 31.8 31.8 31.8 31.8 31.8 Property, Plant and Equipment 57.2 57.3 60.2 62.7 64.8 Other Equity 1175.7 197.6 21
Slide 24: Historical Consolidated Cash Flow Statement
Historical Consolidated Cash Flow Statement GY sastasundar elute e MO CMO Ey) WE Vera Mar-20 Mar-19 Mar-18 Cash Flow from Operating Activities Profit before Tax 1,109.5 (16.4) (57.6) (41.8) (12.4) Adjustment for Non-Operating Items 1,151.0 (3.2) 48 7.8 5.4 Operating Profit before Working Capital Cha
Slide 25: Being Genuine is Our Core Value, Being Child is Our Culture
‘Being Genuine’ is Our Core Value “Being Child’ is Our Culture Nothing can be more Genuine than our Mothers’ Love BEING BEING GENUINE CHILD OUR CORE VALUE IS OUR CULTURE We ensure that all our products and services are 100% Genuine. Like Child- 'Innovate', ‘Don’t Discriminate’, ‘Connect Emotionally’
Slide 26: SastaSundar Ventures Limited contact details
Company: SastaSundar SastaSundar Ventures Limited CIN: L65993WB1989PLC047002 Mr. Pratap Singh - Company Secretary Email Id : investors@sastasundarcom www-.sastasundarventures.com Investor Relations Partner: @ orient capital Orient Capital (a division of Link Group) Payal Dave Rasika Sawant paval.dav
Sastasundar Ventures — Q3 FY2023 Earnings Presentation on 6ix